Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $345.1 million.

  • Beam Therapeutics' Total Liabilities fell 920.17% to $345.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $345.1 million, marking a year-over-year decrease of 920.17%. This contributed to the annual value of $370.3 million for FY2024, which is 2259.81% down from last year.
  • Latest data reveals that Beam Therapeutics reported Total Liabilities of $345.1 million as of Q3 2025, which was down 920.17% from $344.3 million recorded in Q2 2025.
  • Beam Therapeutics' Total Liabilities' 5-year high stood at $647.7 million during Q4 2021, with a 5-year trough of $270.8 million in Q1 2021.
  • Its 5-year average for Total Liabilities is $462.8 million, with a median of $446.3 million in 2024.
  • Per our database at Business Quant, Beam Therapeutics' Total Liabilities surged by 39820.98% in 2021 and then plummeted by 2571.24% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Total Liabilities stood at $647.7 million in 2021, then dropped by 6.09% to $608.2 million in 2022, then decreased by 21.35% to $478.4 million in 2023, then dropped by 22.6% to $370.3 million in 2024, then dropped by 6.81% to $345.1 million in 2025.
  • Its Total Liabilities was $345.1 million in Q3 2025, compared to $344.3 million in Q2 2025 and $343.8 million in Q1 2025.